Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus

American Journal of Physiology - Renal Physiology

Volumn 291, Issue 3, 2006, Pages

  Rodriguez, Walter E ^a   Tyagi, Neetu ^a   Joshua, Irving G ^a   Passmore, John C ^a   Fleming, John T ^a   Falcone, Jeff C ^a   Tyagi, Suresh C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Acetylcholine; Homocysteine clearance; Kidney injury molecule; Matrix metalloproteinase; Nitric oxide; Phenylephrine; Preglomerular arteriole

Indexed keywords

ACETYLCHOLINE; GELATINASE A; GELATINASE B; GLUCOSE; HOMOCYSTEINE; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENYLEPHRINE; PIOGLITAZONE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GLOMERULOPATHY; GLOMERULUS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GRAVIMETRY; HEMODYNAMIC PARAMETERS; KIDNEY BLOOD FLOW; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR RESISTANCE;

EID: 33748419495     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00398.2005     Document Type: Article

References (43)

1. Bicikova M, Hampl R, Hill M, Stanicka S, Tallova J, and Vondra K. Steroids, sex hormone-binding globulin, homocysteine, selected hormones and markers of lipid and carbohydrate metabolism in patients with severe hypothyroidism and their changes following thyroid hormone supplementation. Clin Chem Lab Med 41: 284-292, 2003.
2. Bissonnette R, Treacy E, Rozen R, Boucher B, Cohn JS, and Genest J. Fenofibrate raises plasma homocysteine levels in the fasted and fed states. Atherosclerosis 155: 455-462, 2001.
3. Camp T, Smiley L, Hayden MR, and Tyagi SC. Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats. J Hypertens 21: 1719-1727, 2003.
4. Carroll JF and Tyagi SC. Extracellular matrix remodeling in heart of homocysteinemic obese rabbit. Am J Hypertens 18: 692-698, 2005.
5. Dicker-Brown A, Fonseca VA, Fink LM, and Kern PA. The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine-beta-synthase: studies in hepatocytes. Atherosclerosis 158: 297-301, 2001.
6. Dong FQ, Li H, Cai WM, Tao J, Li Q, Ruan Y, Zheng FP, and Zhang Z. Effects of pioglitazone on expressions of matrix metalloproteinases 2 and 9 in kidneys of diabetic rats. Chin Med J (Engl) 117: 1040-1044, 2004.
7. Eassiouny HS, Song RH, Hong XF, Singh A, Kocharyan H, and Glagov S. Flow regulation of 72-kD collagenase IV (MMP-2) and experimental arterial injury. Circulation 98: 157-163, 1998.
8. Emoto M, Kanda H, Shoji T, Kawagishi T, Lomatsu M, Mori K, Tahara H, Ishimura E, Inaba M, Okuno Y, and Nishizawa Y. Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 24: 533-538, 2001.
9. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, and Rees A. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 101: 1773-1779, 2000.
10. Fukagawa NK, Minaker KU, Young VR, and Rowe JW. Insulin dose-dependent reductions in plasma amino acids in man. Am J Physiol Endocrinol Metab 250: E13-E17, 1986.
11. Griendling KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000.
12. Henegar JR, Bigler SA, Henegar LK, Tyagi SC, and Hall JE. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 12: 1211-1217, 2001.
13. Hunt MJ and Tyagi SC. Peroxisome proliferators compete and ameliorate homocysteine-mediated endocardial endothelial cells activation. Am J Physiol Cell Physiol 283: C1073-C1079, 2002.
14. Ichimura T, Hung CC, Yang SA, Stevens JL, and Bonventre JV. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 286: F552-F563, 2004.
15. Kaye JM, Stanton KG, McCann VJ, Vasikaran VB, Taylors RR, and van Bockxmeer FM. Homocysteine, folate, methylene-tetrahydrofolate reductase genotype and vascular morbidity in diabetic subjects. Clinical Science; 102: 631-637, 2002.
16. Maeda M, Yabuki A, Suzuki S, Matsumoto M, Taniguchi K, and Nishinakagawa H. Renal lesions in spontaneous insulin-dependent diabetes mellitus in the nonobese diabetic mouse: acute phase of diabetes. Vet Pathol 40: 187-195, 2003.
17. McLennan SV, Fisher E, Martell SY, Death AK, Williams PF, Lyons JG, and Yue DK. Effects of glucose on MMP, and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int Suppl 77: S81-S87, 2000.
18. McLennan SV, Martell SK, and Yue DK. Effects of Mg-glycation of MMP activities: possible role in diabetic nephropathy. Diabetes 51: 2612-2618, 2002.
19. McLennan SV, Wang XY, Moreno V, Yue DK, and Twigg SM. Connective tissue growth factor mediates high glucose effects on matrix degradation through TIMP-1: implications for diabetic nephropathy. Endocrinology 145: 5646-5655, 2004.
20. Miller A, Mujumdar V, Shek E, Guillot J, Angelo M, Palmer L, and Tyagi SC. Hyperhomocysteinemia induces multiorgan damage. Heart Vessels 15: 135-143, 2000.
21. Mujumdar VS, Aru GM, and Tyagi SC. Induction of oxidative stress by homocysteine impairs endothelial function. J Cell Biochem 82: 491-500, 2001.
22. Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Wilson TM, Glass CK, and Milburn MV. Ligand binding and co-activator assembly of the PPAR. Nature 395: 137-143, 1998.
23. Papaioannou VE and Fox JG. Efficacy of tribromoethanol anesthesia in mice. Lab Anim Sci 43: 189-192, 1993.
24. Passmore JC, Whitescarver SA, Ott CE, and Kotchen TA. Importance of chloride for DOCA-salt hypertension in the rat. Hypertension 7: I-115-I-120, 1985.
25. Petro AE, Cotter J, Cooper DA, Peters JR, Surwit SJ, and Surwit RS. Fat, carbohydrate, and calories in the development of diabetes and obesity in the C57BL/6J mouse. Metabolism 53: 454-457, 2004.
26. Qi Z, Whitt I, Mehta A, Jin J, Zhao M, Harris R, Fogo AB, and Breyer MD. Serial determination of glomerular filtration rate in conscious mice using FITC-inulin clearance. Am J Physiol Renal Physiol 286: F590-F596, 2004.
27. Rucklidge GJ, Milne G, McGaw BA, Milne E, and Robins SP. Turnover rates of different collagen types measured by isotope ratio mass spectrometry. Biochim Biophys Acta 11: 1156-1157, 1992.
28. Satoh M, Fujimoto S, Haruna Y, Sayaka A, Hideyuki H, Norio K, Tamaki S, Tsujioka K, Makino H, and Kashihara N. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 288: F1144-F1152, 2005.
29. Senior RM, Griffin GL, Eliszar CJ, Shapiro SD, Goldberg GI, and Welgus HG. Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem 266: 7870-7875, 1991.
30. Shcherbak NS, Shutskaya ZV, Sheidina AM, Larionova VI, and Schwartz El. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in IDDM patients. Mol Genet Metab 68: 375-378, 1999.
31. Sood HS, Hunt MJ, and Tyagi SC. Peroxisome proliferator ameliorates endothelial dysfunction in a murine model of hyperhomocysteinemia. Am J Physiol Lung Cell Mol Physiol 284: L333-L341, 2003.
32. Surwit RS, Feinglos MN, Rodin J, Sutherland A, Petro AE, Opara EC, Kuhn CM, and Rebuffe-Scrive M. Differential effects of fat and sucrose on the development of obesity and diabetes in C57BL/6J and A/J mice. Metabolism 44: 645-651, 1995.
33. Surwit RS, Kuhn CM, Cochrane C, McCubbin JA, and Feinglos MN. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 9: 1163-1167, 1988.
34. Tarone RE. A modified Bonferroni method for discrete data. Biometrics 46: 515, 1990.
35. Tyagi SC, Meyer L, Schmaltz RA, Reddy HK, and Voelker DJ. Proteinases and restenosis in human coronary artery: extracellular matrix production exceeds the expression of proteolytic activity. Atherosclerosis 116: 43-57, 1995.
36. Tyagi N, Moshal KS, Lominadze D, Ovechkin AV, and Tyagi SC. Homocysteine-dependent cardiac remodeling and endothelial-myocyte coupling in a 2 kidney, 1 clip Goldblatt hypertension mouse model. Can J Physiol Pharmacol 83: 583-594, 2005.
37. Tyagi SC, Smiley LM, Mujumdar VS, Clonts B, and Parker JL. Reduction-oxidation (redox) and vascular tissue level of homocyst(e)ine in human coronary atherosclerotic lesions and role in vascular ECM remodeling and vascular tone. Mol Cell Biochem 181: 107-116, 1998.
38. Wang Z, Jiang T, Li J, Proctor G, McManaman JL, Lucia S, Chua S, and Levi M. Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVB db/db mice with type 2 diabetes. Diabetes 54: 2328-2335, 2005.
39. Wei P, Lane PH, Lane JT, Padanilam BJ, and Sansom SC. Glomerular structural and functional changes in a high-fat diet mouse model of early-stage type 2 diabetes. Diabetologia 47: 1541-1549, 2004.
40. Wolin MS. Interaction of oxidants with vascular signaling systems. Arteriocler Thromb Vasc Biol 20: 1430-1442, 2000.
41. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Bergiund L, and Beme C. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 55: 1028-1035, 1999.
42. Yoshida T, Tang SS, Hsiao LL, Jensen RV, Ingelfinger JR, and Gullans SR. Global analysis of gene expression in renal ischemia-reperfusion in the mouse. Biochem Biophys Res Commun 291: 787-794, 2002.
43. Zhang J and Hill CE. Differential connexin expression in preglomerular and postglomerular vasculature: accentuation during diabetes. Kidney Int 68: 1171-1185, 2005.